Bioaffinity Technologies Warrant Stock Debt To Equity
BIAFW Stock | USD 0.60 0.01 1.64% |
bioAffinity Technologies Warrant fundamentals help investors to digest information that contributes to BioAffinity Technologies' financial success or failures. It also enables traders to predict the movement of BioAffinity Stock. The fundamental analysis module provides a way to measure BioAffinity Technologies' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BioAffinity Technologies stock.
Last Reported | Projected for Next Year | ||
Debt To Equity | 0.29 | 0.31 |
BioAffinity | Debt To Equity |
bioAffinity Technologies Warrant Company Debt To Equity Analysis
BioAffinity Technologies' Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current BioAffinity Technologies Debt To Equity | 0.31 |
Most of BioAffinity Technologies' fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, bioAffinity Technologies Warrant is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
BioAffinity Debt To Equity Driver Correlations
Understanding the fundamental principles of building solid financial models for BioAffinity Technologies is extremely important. It helps to project a fair market value of BioAffinity Stock properly, considering its historical fundamentals such as Debt To Equity. Since BioAffinity Technologies' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of BioAffinity Technologies' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of BioAffinity Technologies' interrelated accounts and indicators.
Click cells to compare fundamentals
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
Competition |
BioAffinity Total Stockholder Equity
Total Stockholder Equity |
|
Did you try this?
Run Bollinger Bands Now
Bollinger BandsUse Bollinger Bands indicator to analyze target price for a given investing horizon |
All Next | Launch Module |
BioAffinity Fundamentals
Return On Equity | -1.52 | ||||
Return On Asset | -0.7 | ||||
Profit Margin | (1.19) % | ||||
Operating Margin | (0.87) % | ||||
Revenue | 2.53 M | ||||
Gross Profit | 2.6 M | ||||
EBITDA | (7.63 M) | ||||
Net Income | (7.94 M) | ||||
Cash And Equivalents | 214.4 K | ||||
Cash Per Share | 0.08 X | ||||
Total Debt | 1.58 M | ||||
Current Ratio | 0.02 X | ||||
Book Value Per Share | 0.52 X | ||||
Cash Flow From Operations | (6.04 M) | ||||
Number Of Employees | 75 | ||||
Beta | 3.12 | ||||
Total Asset | 8.22 M | ||||
Retained Earnings | (44.6 M) | ||||
Working Capital | 1.72 M | ||||
Net Asset | 8.22 M |
About BioAffinity Technologies Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze bioAffinity Technologies Warrant's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioAffinity Technologies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of bioAffinity Technologies Warrant based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for BioAffinity Stock Analysis
When running BioAffinity Technologies' price analysis, check to measure BioAffinity Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioAffinity Technologies is operating at the current time. Most of BioAffinity Technologies' value examination focuses on studying past and present price action to predict the probability of BioAffinity Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioAffinity Technologies' price. Additionally, you may evaluate how the addition of BioAffinity Technologies to your portfolios can decrease your overall portfolio volatility.